All news
>
Presenting Groundbreaking Advances at Onco Startup Summit 2024

Presenting Groundbreaking Advances at Onco Startup Summit 2024

PepKon
April 4, 2024
PepKon is honored to be selected to present at the Onco Startup Summit 2024, an exclusive event during the IFODS Congress in Paris. This platform will allow us to showcase our advancements in peptide-based oncology treatments to a distinguished audience of oncologists, investors, and industry experts.

PepKon is excited to participate in the upcoming Onco Startup Summit 2024, taking place during the IFODS Congress in Paris. As one of 10 selected startups, we will have the opportunity to present our innovative approach to peptide-based cancer therapies before a panel of oncologists, investors, and potential partners.

Representing PepKon, Jonathan Levy, our CEO, will highlight our latest advancements in AI-assisted peptide drug discovery, computational peptide design, and targeted peptide cancer treatments. This event provides a unique stage to engage with leading experts and discuss the future of peptide therapeutics development in oncology.

We extend our gratitude to the Onco Startup Summit organizers for creating this invaluable opportunity to share and collaborate within the biotech and oncology community.

We look forward to connecting with key players in the industry and continuing our mission to advance AI-driven peptide drug discovery and revolutionize oncology-focused peptide engineering.

‍

Find other news

Pepkon at J.P.Morgan Healthcare Conference 2025

Taking Pepkon's peptide expertise to JPM 2025. Connecting, innovating, and shaping the future of biotech.

Pepkon advances to Semi-finals of EIT Health Catapult 2024-2025

Driving innovation in peptide therapeutics, PepKon secures a spot among Europe’s top biotech start-ups in the prestigious EIT Health Catapult program.